2. Sensitivity analyses: Clinically important response (defined by study).

FLUPHENAZINE (ORAL) vs AMISULPIRIDE
No trial reported relevant data for the primary outcome
FLUPHENAZINE (ORAL) vs RISPERIDONE
2.1.1 short term (up to 12 weeks)
Conley 2005	2	13	3	13	100.0%	0.67 [0.13 to 3.35]
Leaving the study	1		1
Opposite assumption*	3		4			0.75 [0.21 to 2.71]
FLUPHENAZINE (ORAL) vs QUETIAPINE
3.1.1 short term (up to 12 weeks)
Conley 2005	2	13	3	12	100.0%	0.62 [0.12 to 3.07]
Leaving the study	1		4
Opposite assumption	3		7			0.40 [0.13 to 1.19]
FLUPHENAZINE (ORAL) vs OLANZAPINE
4.1.1 short term (up to 12 weeks)
Dossenbach 1998	20	30	15	30	100.0%	1.33 [0.86 to 2.07]
Leaving the study	7		7
Opposite assumption	27		22			1.23 [0.96 to 1.57]
4.1.2 medium term (13 to 26 weeks)
Dossenbach 1998	16	30	10	30	100.0%	1.60 [0.87 to 2.94]
Leaving the study	7		7
Opposite assumption	23		17			1.35 [0.93 to 1.96]

* We currently assume that those who left early have the same rate as 'events' as those who stayed in. This means that for each time the outcome is reported the assumption has negligible effect on the final calculation of RR. For 'opposite assumption' we have pushed the assumption further ‐ assumed that all who leave have done so because they have the outcome of interest.